Proteostasis Therapeutics
Merged with Yumanity Therapeutics in 2020
Developing therapies targeting protein misfolding diseases.
Investment Team
Sector
Life SciencesCategory
TherapeuticsStatus
PublicLocation
Cambridge, MAInitial Investment
2008
Developing therapies targeting protein misfolding diseases.
Proteostasis Therapeutics is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics went public in 2016 (NASDAQ: PTI). The company merged with Yumanity Therapeutics in 2020 and is no longer traded with the ticker symbol PTI.